Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Blood Group B May Indicate Shorter Survival in DLBCL

Key clinical point: A retrospective study suggests the ABO blood group has prognostic significance for patients with diffuse large B-cell lymphoma (DLBCL).

Major finding: Among 240 patients with DLBCL, the presence of blood group B was associated with a lower 5-year overall survival rate than non-B blood groups (36.3% vs. 56.9%; P less than .01).

Study details: A single-center retrospective cohort study of 523 patients with malignant lymphoma.

Disclosures: No funding sources were reported. The authors reported having no conflicts of interest.


Osada Y et al. Clin Lymphoma Myeloma Leuk. 2019 Oct 1. doi: 10.1016/j.clml.2019.09.607